Trial Profile
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure With Reduced Ejection Fraction and Decreased Exercise Tolerance
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms METEORIC-HF
- Sponsors Amgen
- 19 Jul 2022 Primary endpoint has not been met. (Change in peak oxygen uptake (VO2) on cardiopulmonary exercise testing from baseline to Week 20), as per results published in the JAMA: the Journal of the American Medical Association.
- 19 Jul 2022 Results published in the JAMA: the Journal of the American Medical Association.
- 09 May 2022 According to a Cytokinetics media release, results from this study were published in the Journal of Circulation: Heart Failure.